NVO
Novo Nordisk A/S · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -6.3% ·
net new positions -6.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 347.39K | $13.21M | n/a | −1 |
| Q2 2026 | 132 | 0 | 235.88M | $11.31B | +12 | −13 |
| Q1 2026 | 134 | -8 | 242.80M | $8.91B | +5 | −13 |
| Q4 2025 | 140 | +1 | 228.46M | $11.63B | +3 | −2 |
| Q3 2025 | 19 | -1 | 80.89M | $4.49B | +2 | −3 |
| Q2 2025 | 17 | -1 | 53.30M | $3.68B | +1 | −2 |
| Q1 2025 | 16 | 0 | 43.10M | $3.00B | n/a | n/a |
| Q4 2024 | 16 | -1 | 48.20M | $4.15B | +1 | −2 |
| Q3 2024 | 16 | -1 | 43.13M | $5.09B | +1 | −2 |
| Q2 2024 | 17 | n/a | 46.04M | $6.57B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fisher Asset Management ✦ | 13.31M | -0.5% | $1.58B | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 9.58M | +0.8% | $1.14B | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 8.19M | -10.7% | $975.10M | 1.5% | ▼ Trim | 2 | SEC ↗ |
| 4 | Capital World Investors ✦ | 4.45M | -0.2% | $530.73M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Markel Group ✦ | 2.15M | 0.0% | $256.00M | 2.3% | Held | 2 | SEC ↗ ×2 |
| 6 | Tiger Global Management ✦ | 1.27M | 0.0% | $151.10M | 0.6% | Held | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 905.59K | +1839.2% | $107.83M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 794.12K | +4.6% | $94.56M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 9 | Millennium Management ✦ | 709.46K | -67.2% | $84.48M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 411.64K | -52.9% | $49.01M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 352.88K | New | $42.02M | 0.0% | New | 1 | SEC ↗ ×5 |
| 12 | Coatue Management ✦ | 326.36K | +892.1% | $38.86M | 0.1% | ▲ Add | 2 | SEC ↗ ×5 |
| 13 | Marshall Wace ✦ | 181.30K | -73.8% | $21.59M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 14 | Arrowstreet Capital ✦ | 450.80K | +13.9% | $8.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 50.99K | +197.1% | $6.07M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 16 | Baillie Gifford ✦ | 53 | +20.4% | $6,311 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $42.02M | 0.0% |
Exited
| Point72 Asset Management | $137.15M | was 0.5% |
| Soros Fund Management | $24.98M | was 0.8% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1.21M shares, $43.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.